25th Nov 2024 08:51
(Alliance News) - AstraZeneca PLC on Monday said its Truqap combination in a type of prostate cancer showed a statistically significant improvement in a form of progression-free survival.
The Cambridge, England-based pharmaceutical company said the data came from a phase 3 trial which enrolled over 1,000 adults suffering from a type of prostate cancer.
It showed Truqap in combination with abiraterone and androgen deprivation therapy demonstrated a statistically significant and clinically meaningful improvement in the primary endpoint of radiographic progression-free survival versus those receiving abiraterone, ADT and a placebo. Abiraterone is a hormone therapy.
Overall survival data were immature at the time of the analysis, but the Truqap combination showed an early trend towards an overall survival improvement compared to abiraterone and ADT with placebo, AstraZeneca noted.
Susan Galbraith, executive vice president, Oncology research & development at AstraZeneca said: "These results show for the first time, that adding an AKT inhibitor to a standard-of-care therapy can provide benefit to patients with a biomarker of PTEN-deficient metastatic hormone-sensitive prostate cancer. By targeting a key driver of the disease, we have been able to improve upon current therapies and demonstrate the potential role of this combination in an area of critical unmet need. It will be important to see greater maturity in key secondary endpoints including overall survival."
AKT inhibitors are drugs that block the activity of Akt, an enzyme involved in cancer cell growth and their ability to survive and resist treatment.
AstraZeneca shares were up 0.3% at 10,502.00 pence each on Monday morning in London.
By Tom Budszus, Alliance News slot editor
Comments and questions to [email protected]
Copyright 2024 Alliance News Ltd. All Rights Reserved.